ABVX vs ARRY

Analysts rate Abivax S.

A. (ABVX) a "Buy" — based on 12 analyst ratings — the highest consensus in this comparison. The "better buy" depends entirely on your goals: growth investors should weight revenue trajectory, value investors should weight P/E and PEG, and income investors should weight dividend yield and streak.

Over the past 5 years, Abivax S.

A. (ABVX) delivered a total return of +1115%, compared to -53. 9% for Array Technologies, Inc. (ARRY). Over 10 years, the gap is even starker: ABVX returned +1115% versus ARRY's -79. 6%. Past returns do not guarantee future results, and the stock with the higher historical return may already have its best growth priced in.

By beta (market sensitivity over 5 years), Abivax S.

A. (ABVX) is the lower-risk stock at 1. 02β versus Array Technologies, Inc. 's 2. 34β — meaning ARRY is approximately 130% more volatile than ABVX relative to the S&P 500. On balance sheet safety, Abivax S. A. (ABVX) carries a lower debt/equity ratio of 7% versus 3% for Array Technologies, Inc. — giving it more financial flexibility in a downturn.

On earnings-per-share growth, the picture is similar: Array Technologies, Inc.

grew EPS 62. 6% year-over-year, compared to -66. 1% for Abivax S. A.. Higher growth typically commands a higher valuation multiple — check whether the premium P/E or P/S is justified by the growth rate using the PEG ratio.

Abivax S.

A. (ABVX) is the more profitable company, earning 0. 0% net margin versus -4. 1% for Array Technologies, Inc. — meaning it keeps 0. 0% of every revenue dollar as bottom-line profit. Operating margin tells a similar story: ARRY leads at 6. 6% versus 0. 0% for ABVX. At the gross margin level — before operating expenses — ARRY leads at 21. 2%, reflecting greater pricing power or product mix advantage. Stronger margins indicate durable pricing power, lower cost of revenue, or higher mix of software/services. They are one of the clearest signs of business quality.

Analyst consensus price targets imply the most upside for ARRY: 31.

5% to $9. 80.

None of the stocks in this comparison currently pay a material dividend.

All are effectively zero-yield and should be held for capital appreciation rather than income.

For long-horizon retirement investors, Abivax S.

A. (ABVX) is the stronger choice — it scores higher on the combination of lower volatility, dividend reliability, and long-term compounding (low volatility (β 1. 02), +1115% 10Y return). Array Technologies, Inc. (ARRY) carries a higher beta of 2. 34 — meaning larger drawdowns in market downturns, which matters significantly when you cannot wait years for a recovery. Both have compounded well over 10 years (ABVX: +1115%, ARRY: -79. 6%), confirming both are viable long-term holds — but the lower-volatility option typically results in less emotional selling during corrections. Retirement portfolios generally favour predictability over maximum returns. Consult a financial advisor before making allocation decisions.

These companies operate in different sectors (ABVX (Healthcare) and ARRY (Energy)), which means they face different economic cycles, regulatory environments, and macro sensitivities — making direct comparison nuanced.

In terms of investment character: ABVX is a small-cap quality compounder stock; ARRY is a small-cap high-growth stock. These fundamental differences mean investors should not choose between them on a single metric — the "better stock" depends entirely on which of these characteristics aligns with your investment strategy.